Compare NIO Inc. (NIO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs BIO-TECHNE Corp — how do they compare? NIO Inc. trades at $3.45 (market cap $8.67B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and BIO-TECHNE Corp for 63 Days on average.
| NIO | TECH | |
|---|---|---|
Market Cap | $8.67B | $11.37B |
Volume | 25,622,800 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $72.61 |
52-Week Low | $3.37 | $43.31 |
Typical Hold Time | 81 Days | 63 Days |
Enterprise Value | $6.57B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.41, down 2.01% today and near its 52-week low of $3.38. The stock shows bearish technical signals with negative moving averages, though oscillators are neutral. Fundamentally, revenue grew to $87.49B in 2025 with improving net margin to -17.8%, but the company remains unprofitable with negative ROE of -332.77%. Recent news highlights a strategic battery-swap partnership with Geely, valued at $2.38B, which could expand NIO's charging network reach.
The outlook remains challenging amid a brutal EV price war in China, though analyst consensus is bullish with a $6.23 price target implying 83% upside. Key risks include persistent losses, high debt, and intense competition. Institutional sentiment is mixed with 50% buy ratings, but the stock's current valuation at 0.51 P/S may attract value investors betting on a long-term turnaround.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
